Accredited Investors Inc. Trims Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Accredited Investors Inc. lessened its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,020 shares of the medical equipment provider’s stock after selling 53 shares during the quarter. Accredited Investors Inc.’s holdings in Intuitive Surgical were worth $454,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Apollon Wealth Management LLC increased its holdings in shares of Intuitive Surgical by 3.2% in the 2nd quarter. Apollon Wealth Management LLC now owns 10,308 shares of the medical equipment provider’s stock valued at $4,586,000 after acquiring an additional 315 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Intuitive Surgical by 0.6% in the 2nd quarter. Nisa Investment Advisors LLC now owns 107,433 shares of the medical equipment provider’s stock valued at $47,792,000 after acquiring an additional 666 shares during the period. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Intuitive Surgical by 12.6% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 8,765 shares of the medical equipment provider’s stock valued at $3,899,000 after acquiring an additional 980 shares during the period. BTC Capital Management Inc. increased its holdings in shares of Intuitive Surgical by 13.5% in the 2nd quarter. BTC Capital Management Inc. now owns 2,536 shares of the medical equipment provider’s stock valued at $1,128,000 after acquiring an additional 302 shares during the period. Finally, Argus Investors Counsel Inc. acquired a new position in shares of Intuitive Surgical in the 2nd quarter valued at $1,456,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In related news, EVP Robert Desantis sold 240 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $464.76, for a total value of $111,542.40. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,558,968.56. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total transaction of $1,304,631.90. Following the transaction, the director now owns 12,275 shares of the company’s stock, valued at approximately $5,441,507.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Robert Desantis sold 240 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $464.76, for a total value of $111,542.40. Following the transaction, the executive vice president now directly owns 5,506 shares in the company, valued at approximately $2,558,968.56. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,309 shares of company stock valued at $6,642,470. 0.90% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on ISRG. JPMorgan Chase & Co. lifted their target price on shares of Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday, July 19th. Morgan Stanley upped their price objective on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Stifel Nicolaus raised their target price on shares of Intuitive Surgical from $430.00 to $475.00 and gave the stock a “buy” rating in a research note on Friday, July 19th. BTIG Research boosted their price target on shares of Intuitive Surgical from $451.00 to $459.00 and gave the stock a “buy” rating in a research note on Monday, July 15th. Finally, The Goldman Sachs Group initiated coverage on shares of Intuitive Surgical in a research report on Thursday, May 30th. They issued a “buy” rating and a $500.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $442.30.

Intuitive Surgical Stock Up 0.7 %

Shares of ISRG traded up $3.18 on Monday, reaching $482.16. The stock had a trading volume of 939,796 shares, compared to its average volume of 1,550,014. The firm has a market capitalization of $171.02 billion, a PE ratio of 87.03, a PEG ratio of 4.97 and a beta of 1.39. The firm has a 50-day moving average of $444.48 and a 200 day moving average of $408.57. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $482.78.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to analysts’ expectations of $1.97 billion. During the same quarter in the prior year, the firm posted $1.18 EPS. The company’s revenue was up 14.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.